Immune checkpoint inhibitor–induced type 1 diabetes mellitus (ICI-T1DM) is a rare but serious immune-related adverse event associated with programmed cell death-1 inhibitors such as nivolumab. The gene discussed is PDCD1; the disease is diabetes mellitus.